What question did this study set out to answer?

September 12, 2003European Journal of Heart Failure

Enhanced Levels of CD154 (CD40 Ligand) on Platelets in Patients with Chronic Heart Failure

View Full Paper

Ask AI

Bookmark

Why the study?

Are levels of platelet-bound CD154 enhanced in patients with chronic heart failure compared to healthy controls?

Key Points

This study aims to assess the levels of CD154 on platelets in patients with chronic heart failure and its potential association with inflammation.
Examined 50 CHF patients (mean age 66.9) and 15 healthy controls (mean age 62.5).
Blood samples were analyzed using flow cytometry for CD154 and P-selectin levels.
Patients' NYHA classification and aspirin use were recorded.
CHF patients exhibited significantly higher platelet-bound CD154 (Median MFI 35.6 vs. 12.8, P<0.001).
Significant correlation found between CD154 expression and NYHA-class severity.
No significant variations in soluble CD154 or CD40 expression on monocytes were observed.

Structured PICO

Are levels of platelet-bound CD154 enhanced in patients with chronic heart failure compared to healthy controls?

Population

50 patients with chronic heart failure (aged 66.9+/-12.6 years, mean ejection fraction 22.1+/-9.2%, NYHA II-IV, 39 of ischemic origin, 11 with idiopathic dilated cardiomyopathy) and 15 healthy controls (aged 62.5+/-9.8 years)

Comparator

Healthy controls

Outcome

Expression of platelet-bound CD154 and P-selectin measured by flow cytometrysurrogate

Patients with chronic heart failure have significantly enhanced levels of platelet-bound CD154, suggesting the CD40-CD154 axis may contribute to the proinflammatory milieu in CHF.

Limitations

Pilot study (small sample size)

Authors

CSChristian StumpfBayreuth Medical Center CLChristoph LehnerThe University of Queensland SESaeed EskafiFriedrich-Alexander-Universität Erlangen-Nürnberg

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Elevated platelet CD154 in CHF supports exploring the CD40-CD154 axis; leaves open any therapeutic role pending trials.

Cite This Study

Stumpf et al. (2003) studied this question.

synapsesocial.com/papers/6a0b82609ead71e723c1f8cb https://doi.org/10.1016/s1388-9842(03)00110-7

Topics

Heart failure HFrEF treatment Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Enhanced Levels of CD154 (CD40 Ligand) on Platelets in Patients with Chronic Heart Failure

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Topics

Enhanced Levels of CD154 (CD40 Ligand) on Platelets in Patients with Chronic Heart Failure

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider